Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-06-20 EDT			5-day change	1st Jan Change
374.70 ^DKK	-3.18%		-16.99%	-47.63%

06-18	Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial	RE
06-18	Zealand Pharma A/S Announces Positive Topline Clinical Results from Part 2 of a Phase 1b Multiple Ascending Dose Trial	CI

Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment

Published on 2024-05-31 at 12:23, updated on 2024-05-31 at 13:07

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Zealand Pharma A/S

Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial	06-18	RE
Zealand Pharma A/S Announces Positive Topline Clinical Results from Part 2 of a Phase 1b Multiple Ascending Dose Trial	06-18	CI
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	06-13	RE
Zealand Pharma A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 04:00 PM	06-11
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial	06-10	RE
Zealand Pharma A/S Submits Marketing Authorization Application to the European Medicines Agency for Glepaglutide in Short Bowel Syndrome	06-02	CI
Zealand Pharma Files EU Marketing Authorization Application for Short Bowel Syndrome Treatment	06-02	MT
Zealand Pharma Applies To EMA For Marketing Authorization For Glepaglutide In Short Bowel Syndrome	06-02	RE
European stocks recover after Trump delays EU tariffs in hopes of deal	05-26	RE
Danish Biotech Zealand Pharma Names Chief Development Officer	05-20	MT
Zealand Pharma A/S Appoints Steven Johnson as Chief Development Officer	05-19	CI
Deutsche Bank lowers its target price for Zealand Pharma to 485 Danish kroner (750), reiterates hold	05-19	FW
Weight-loss drug developers line up to tap lucrative market as competition heats up	05-16	RE
Denmark says Trump's drug pricing order is a step in the wrong direction	05-16	RE
Zealand Pharma A/S Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08:00 AM	05-14
Zealand Pharma A/S Announces Closing of Collaboration and License Agreement with Roche	05-09	CI
DNB lowers target price for Zealand Pharma to DKK 950 (1,000), reiterates buy recommendation - BN	05-09	FW
Zealand Pharma-Roche Deal for Obesity Drug Candidate Takes Effect	05-09	MT
Goldman Sachs lowers target price for Zealand Pharma to DKK 806 (USD 873), reiterates buy rating - BN	05-09	FW
SEB lowers target price for Zealand Pharma to DKK 780 (850), reiterates buy recommendation - BN	05-09	FW
Zealand Pharma A/S, Q1 2025 Earnings Call, May 08, 2025	05-08
Zealand Pharma Keeps Guidance For 2025 Unchanged	05-08	RE
Zealand Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2025	05-07	CI
Kempen Lowers Zealand Pharma PT, Keeps at Buy	05-05	MT
Kempen lowers target price for Zealand Pharma to DKK 750 (900), reiterates buy recommendation - BN	05-05	FW

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2023, the Group had a portfolio of 7 products in clinical development (including 3 in phase III, 3 in phase II and 1 in phase I), and 3 products in preclinical development.

Employees

385

Sector

Biotechnology & Medical Research

Calendar

08-14 - Q2 2025 Earnings Release

More about the company